Related Experiment Video
Updated: Jun 2, 2026

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
Published on: August 15, 2019
Adoptive immunotherapy of experimental ovarian-cancer using activated human monocytes and the human
1UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT OBSTET & GYNAECOL,LEICESTER LE1 7RH,ENGLAND.
Abstract:
We have examined the ability of the ovarian cancer cell-line OWmM1 to grow intraperitoneally in athymic ('nude') mice. The cell-line was tumorigenic and metastatic in a manner that paralleled the human disease; the metastatic nodules implanted onto the peritoneal surface, the diaphragm and the mesentery. The resulting tumour formed a clear ascitic fluid and peritoneal carcinomatosis. Adoptive transfer of activated human monocytes to the peritoneal cavity of tumour-bearing animals showed no increase in survival, while antibody alone produced a modest survival benefit (2-4 days). Administration of the human monoclonal antibody anti-14C1 and monocyte therapy together increased the benefit further and resulted in approximately 30% of the animals surviving until the end of the experiment (100 days).
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tumor Immunotherapy

